World Health Organization Generic Protocol to Assess Drug-Resistant HIV among Children <18 Months of Age and Newly Diagnosed with HIV in Resource-Limited Countries

Clinical Infectious Diseases

Volumn 54, Issue SUPPL. 4, 2012, Pages

  Bertagnolio, Silvia ^a   Penazzato, Martina ^b   Jordan, Michael R ^a,c   Persaud, Deborah ^d   Mofenson, Lynne M ^e   Bennett, Diane E ^f  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF PADOVA   (Italy)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE; RIFAMPICIN; RITONAVIR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL PROTOCOL; DISEASE SURVEILLANCE; DRIED BLOOD SPOT TESTING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

AFRICA; ANTI-RETROVIRAL AGENTS; DEVELOPING COUNTRIES; DRIED BLOOD SPOT TESTING; DRUG RESISTANCE, VIRAL; EARLY DIAGNOSIS; FEMALE; GENOTYPING TECHNIQUES; HIV; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; WORLD HEALTH ORGANIZATION;

EID: 84860381470     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis003     Document Type: Article

References (42)

1. World Health Organization, Joint United Nations Program on HIV/AIDS, UNICEF. Global HIV/AIDS response. Epidemic update and health sector progress towards universal access. Geneva, Switzerland: World Health Organization, 2011. Available at: http://www.who.int/hiv/pub/progress-report2011/en/index.html. Accessed 7 December 2011.
2. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infections in infants. Geneva, Switzerland:World Health Organization, 2010:1-106. Available at: http://www.who.int/hiv/pub/mtct/ antiretroviral2010/en/index.html. Accessed 13 June 2011.
3. World Health Organization. Antiretroviral therapy in infants and children: towards universal access. Recommendations for a public health approach: 2010 revision. Geneva, Switzerland: World Health Organization, 2010. Available at: http://www.who.int/hiv/pub/paediatric/infants2010/en/. Accessed 13 June 2011.
4. Ergun-Longmire B, Lin-Su K, Dunn AM, et al. Effects of protease inhibitors on glucose tolerance, lipid metabolism, and body composition in children and adolescents infected with human immunodeficiency virus. Endocr Pract 2006; 12:514-21. (Pubitemid 46456038)
5. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009; 23: 1109-18.
6. Lainka E, Oezbek S, Falck M, Ndagijimana J, Niehues T. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy. Pediatrics 2002; 110:e56.
7. Moorthy A, Gupta A, Bhosale R, et al. Nevirapine resistance and breast milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS One 2009; 4:e4096.
8. Persaud D, Palumbo P, Ziemniak C, et al. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J Infect Dis 2007; 195:1402-10. (Pubitemid 46717457)
9. Arrivé E, Newell ML, Ekouevi DK, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007; 36:1009-21. (Pubitemid 350018545)
10. Church JD, Omer SB, Guay LA, et al. Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV-infected despite receiving single-dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. J Infect Dis 2008; 198: 1075-82.
11. Lidstrom J, Li Q, Hoover DR, et al. Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero. AIDS 2010; 24:381-6.
12. Taylor BS, Hunt G, Abrams EJ, et al. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses 2011; 27:965-56.
13. Coovadia A, Abrams EJ, Stehlau R, et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA 2010; 304: 1082-90.
14. Moorthy A, Kuhn L, Coovadia A, et al. Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children. Clin Infect Dis 2011; 52:514-21.
15. McSherry GD, Shapiro DE, Coombs RW, et al. The effects of zidovudine in the subset of infants infected with human immunodeficiency virus type-1 (Pediatric AIDS Clinical Trials Group Protocol 076). J Pediatr 1999; 134:717-24. (Pubitemid 30186815)
16. Mofenson LM, Lambert JS, Stiem E, et al. Association of zidovuidine (ZDV) genotypic resistance with perinatal HIV transmission in women receiving ZDV in Pediatric Clinical Trials Group Protocol 185 [abstract 1229]. In: Program and abstracts of the 13th International AIDS Conference. Durban, South Africa, 2000.
17. Giuliano M, Galluzzo CM, Germinario EA, et al. Selection of resistance mutations in children receiving prophylaxis with lamivudine or nevirapine for the prevention of postnatal transmission of HIV. J Acquir Immune Defic Syndr 2006; 42:131-3. (Pubitemid 43947960)
18. Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med 2011; 8:e1000430.
19. Lidstrom J, Kumwenda N, Kafulafula G, et al. Antiretroviral treatment of HIV-infected women can induce multiclass drug resistance in their breast-feeding infants [abstract 135]. In: Program and abstracts of the 18th International HIV Drug Resistance Workshop. Fort Myers, Florida: Antiviral Therapy 2009; 14:A158. Available at: http://www.informedhorizons.com/resistance2009/pdf/AbstractBook- RW2009-070209.pdf.Accessed 13 June 2011.
20. Lidstrom J, Guay L, Musoke P, et al. Multi-class drug resistance arises frequently in HIV-infected breastfeeding infants whose mothers initiate HAART postpartum [oral abstract 920]. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, California: CROI, 2010. Available at: http://www.retroconference.org/2010/Abstracts/38186.htm. Accessed 13 June 2011.
21. Fogel J, Li Q, Taha TE, et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis 2011; 52:1069-76.
22. Kunz A, Mugenyi K, Karcher H, et al. Nevirapine is detectable in breast milk up to 2 weeks after single dose [abstract TUPE0353]. In: Program and abstracts of the 16th International AIDS Conference. Toronto, Canada: International AIDS Society, 2006. Available at: http://www.iasociety.org/ Default. aspx?pageId511&abstractId52194851. Accessed 14 June 2011.
23. Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2009; 53:1170-6.
24. Mirochnick M, Best BM, Clarke DF. Antiretroviral pharmacology: special issues regarding pregnant women and neonates. Clin Perinatol 2010; 37:907-27, xi.
25. Lee EJ, Kantor R, Zijenah L, et al. Breast milk shedding of drugresistant HIV-1 subtype C in women exposed to single-dose nevirapine. J Infect Dis 2005; 192:1260-4. (Pubitemid 41368427)
26. Farr SL, Nelson JA, Ng'ombe TJ, et al. Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi. J Acquir Immune Defic Syndr 2010; 54:515-23.
27. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-47. (Pubitemid 46089674)
28. Lockman S, Smeaton L, Ogwu A, et al. Outcomes on nevirapine-based HAART following receipt of peripartum single-dose nevirapine or placebo, Botswana [poster 955]. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada: CROI, 2009. Available at: http://www.retroconference.org/2009/Abstracts/36058.htm. Accessed 13 June 2011.
29. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010; 363:1510-20.
30. Kuhn L, Coovadia A, Meyers T, et al. Long-term outcomes of switching children to NVP-based therapy after initial suppression with a PI-based regimen [oral abstract 128]. In: Program and abstracts of the 18th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts: CROI, 2011. Available at: http://www.retroconference.org/2011/Abstracts/41025.htm. Accessed 13 June 2011.
31. Creek T, Tanuri A, Smith M, et al. Early diagnosis of human immunodeficiency virus in infants using polymerase chain reaction on dried blood spots in Botswana's national program for prevention of mother-to-child transmission. Pediatr Infect Dis J 2008; 27:22-6.
32. Cherutich P, Inwani I, Nduati R, Mbori-Ngacha D. Optimizing paediatric HIV care in Kenya: challenges in early infant diagnosis. Bull World Health Organ 2008; 86:155-60. (Pubitemid 351213719)
33. Ciaranello AL, Park JE, Ramirez-Avila L, Freedberg KA, Walensky RP, Leroy V. Early infant HIV-1 diagnosis programs in resource limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med 2011; 9:59.
34. Lofgren SM, Morrissey AB, Chevallier CC, et al. Evaluation of a dried blood spot HIV-1 RNA program for early infant diagnosis and viral load monitoring at rural and remote healthcare facilities. AIDS 2009; 23:2459-66.
35. Bertagnolio S, Parkin NT, Jordan M, Brooks J, Garcia-Lerma JG. Dried blood spots for HIV-1 drug resistance and viral load testing: a review of current knowledge and WHO efforts for global HIV drug resistance surveillance. AIDS Rev 2010; 12:195-208.
36. Buckton AJ. New methods for the surveillance of HIV drug resistance in the resource poor world. Curr Opin Infect Dis 2008; 12:653-8.
37. Yang C, McNulty A, Diallo K, et al. Development and application of a broadly sensitive dried-blood-spot-based genotyping assay for global surveillance of HIV-1 drug resistance. J Clin Microbiol 2010; 48:3158-64.
38. World Health Organization.WHO manual for HIV drug resistance testing using dried blood spot specimens. Geneva, Switzerland: World Health Organization, 2010:1-29. Available at: http://www.who.int/hiv/topics/ drugresistance/dbs-protocol.pdf.Accessed 13 June 2011.
39. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006; 42:1608-18.
40. Rollins NC, Dedicoat M, Danaviah S, et al. Prevalence, incidence, and mother-to-child transmission of HIV-1 in rural South Africa. Lancet 2002; 360:389.
41. Rollins N, Little K, Mzolo S, Horwood C, Newell ML. Surveillance of mother-to-child transmission prevention programmes at immunization clinics: the case for universal screening. AIDS 2007; 21:1341-7. (Pubitemid 46883489)
42. Rollins N, Mzolo S, Moodley T, Esterhuizen T, van Rooyen H. Universal HIV testing of infants at immunization clinics: an acceptable and feasible approach for early infant diagnosis in high HIV prevalence settings. AIDS 2009; 23:1851-7.